Avastin.net

Precise VEGF inhibition with Avastin:
understanding the Avastin MoA

 

Direct inhibition of VEGF with Avastin blocks the angiogenic cascade^1–4

• Avastin is a humanised MAb that binds specifically to VEGF, preventing activation of the VEGFR.

• Avastin inhibits VEGF extracellularly and may, therefore, inhibit angiogenesis without disrupting targets outside the VEGF pathway.^1,2

• Based on preclinical models and clinical observations, it has been proposed that Avastin exerts continuous antivascular effects throughout tumour development
  • rapid regression of existing tumour vessels, as shown by significant reductions in microvascular density^5–7
  • normalisation of surviving mature vasculature^6,8
  • ongoing inhibition of both new and recurrent tumour vessel growth.^9,10
   
  
• The net result of the inhibition of VEGF by Avastin is^11–13
  • maintenance of a more functional and normal vasculature
  • potentially improved capacity for drug delivery
  • inhibition of tumour growth and metastasis.
   
• Effects of anti-VEGF agents occur rapidly – sometimes after a single infusion – while the long half-life of the monoclonal antibody allows for a sustained anti-VEGF effect.⁵

For more information on the anti-angiogenic effects of Avastin, please use the links below

Avastin causes regression of tumour vasculature

Avastin normalises existing tumour vasculature

Avastin inhibits new and recurrent vessel growth